Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
Result: A wide range of mutations conferring multi-NRTI resistance were also observed, including M41L (n = 7, 10%), A62V (n = 15, 22%), D67N (n = 10, 15%), K70R (n = 10, 15%), V75I (n = 2, 3%), F77L (n = 1, 1%), Y115F (n = 6, 9%), F116Y (n = 1, 1%), Q151M (n = 1, 1%), L210W (n = 3, 4%), T215Y/F (n = 7, 10%) and (n = 5, 7%), and K219Q/E (n = 4, 6%) and (n = 7, 10%).
Short Communication: In Vitro Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine.
PMID: 26075306
2015
AIDS research and human retroviruses
Abstract: Both patterns, M184V+K65R and Q151M+K65R, have a significant impact on NRTI resistance.
Abstract: Other primary mutations (M184V and Q151M) were selected with ddI treatment in conjunction with K65R only in RTC' viruses.
HIV-1 subtype characteristics of infected persons living in southwestern Greece.
Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and
[Analysis of HIV-1 drug resistance among 1 922 individuals experiencing virological failure of first-line antiretroviral therapy in Henan province].
PMID: 26833003
2015
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Abstract: K65R/N and Q151M complex existed in 23 and 4 patients, respectively.
The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
PMID: 26392486
2015
Antimicrobial agents and chemotherapy
Abstract: BMS-986001 also exhibited full activity against HIV-2 variants whose genomes encoded the single amino acid changes K65R and Q151M in reverse transcriptase, whereas the M184V mutant was 15-fold more resistant to the drug than the parental HIV-2ROD9 strain.
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Introduction: High level and complex profile of HIV-1 drug resistance mutations including Q151M and thymidine analogue mutations (TAMs) in individuals with first-line ART failure and increased prevalence of transmitted drug resistance (TDR) mutations have been reported in recent years, despite more promising initial observations from Africa.
Result: Despite the extensive use of thymidine analogues (TA) like AZT or D4T, TAMs and mutation at codon 151 (Q151M) were not observed.
Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort.
Discussion: The proportion that had complex NRTI resistance patterns, such as three or more TAMs or Q151M complex, was lower (5.5%) than another recent study of 38 children on ART from the same province where 39% had three or more TAMs despite a shorter duration (median = 2.8 yrs; IQR = 1.9- 2.3 yrs) on ART compared with our cohort (median = 3.3 yrs; IQR = 2.5-4.4 yrs).
Discussion: Whilst in most cases the mutations would be unlikely to significantly compromise a second-line regimen based on a ritonavir-boosted PI, five patients had complex mutation patterns (three or more TAMs or Q151M complex) that might substantially limit the future activity of the NRTI class of drugs.
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
HIV mutation literature information.
PMID: 
2015
Journal of medical virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT